Migristene
Migristene (dimetotiazine mesylate) was an oral medicine used for the prevention and treatment of migraine and tension headaches. It acted by inhibiting cerebral vasoconstriction to prevent the onset of headaches, and had anti-serotonin and antihistaminic activity.
Migristene is absent from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Pharmaceuticals and Medical Devices Agency (PMDA) databases, indicating it is no longer authorized in the USA, EU, or Japan. It has largely been superseded by newer migraine therapies, including:
- Triptans (e.g., sumatriptan)
- CGRP antagonists (e.g., rimegepant)
- Ditans (e.g., lasmiditan)
By Megan Lee
Developed by EPG Health for Medthority, independently of any sponsor.
of interest
are looking at
saved
next event
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
